摘要
目的通过信息化手段和药学干预指导心内科患者活血化瘀中成药的使用,为临床合理用药提供依据。方法选取2022年7月至2023年6月在我院心内科住院的384例患者作为研究对象,将其分为对照组(188例,2022年7月至12月)和干预组(196例,2023年1月至6月)。对照组按照本院常规临床路径进行治疗,干预组在常规临床路径的基础上增加信息化手段和药学干预。比较两组的住院时长、费用(住院总费用、药品费用和中成药费用)、临床合理使用情况及活血化瘀中成药不良反应发生情况。结果干预组的药品费用和中成药费用低于对照组,差异具有统计学意义(P<0.05);两组的住院时长和住院总费用比较,差异无统计学意义(P>0.05)。两组患者的活血化瘀中成药品种数比较,差异无统计学意义(P>0.05)。干预组的不合理医嘱数少于对照组,差异具有统计学意义(P=0.000)。两组的活血化瘀中成药不良反应总发生率比较,差异无统计学意义(P=0.327)。结论通过信息化手段和药学干预相结合的方法,可以一定程度上降低药品费用和提高活血化瘀中成药的合理用药,具有可行性。
Objective To guide the use of Chinese patent medicines for promoting blood circulation and removing blood stasis in cardiology department patients by information technology and pharmaceutical intervention,so as to provide a basis for clinical rational drug use.Methods A total of 384 patients hospitalized in the cardiology department of our hospital from July 2022 to June 2023 were selected as the research objects,and the patients were divided into control group(188 cases,from July to December 2022)and intervention group(196 cases,from January to June 2023).The control group was treated according to the routine clinical pathway of our hospital,and the intervention group was treated with information technology and pharmaceutical intervention on the basis of the routine clinical pathway.The hospitalization time,expenses(total hospitalization expenses,drug expenses and Chinese patent medicine expenses),clinical rational use and adverse reactions of Chinese patent medicines for promoting blood circulation and removing blood stasis were compared between the two groups.Results The drug expenses and Chinese patent medicine expenses of the intervention group were lower than those of the control group,and the differences were statistically significant(P<0.05);there were no significant differences in hospitalization time and total hospitalization expenses between the two groups(P>0.05).There was no significant difference in the number of Chinese patent medicines for promoting blood circulation and removing blood stasis between the two groups(P>0.05).The number of unreasonable medical orders in the intervention group was less than that in the control group,and the difference was statistically significant(P=0.000).There was no significant difference in the total incidence of adverse reactions between the two groups of Chinese patent medicines for promoting blood circulation and removing blood stasis(P=0.327).Conclusion Through the combination of information technology and pharmaceutical intervention,the expense of drugs can be reduced to a certain extent and the rational use of Chinese patent medicines for promoting blood circulation and removing blood stasis can be improved,which is feasible.
作者
麦国灿
曾海涛
唐银燕
植伟文
梁邦就
陆嫦萍
MAI Guocan;ZENG Haitao;TANG Yinyan;ZHI Weiwen;LIANG Bangjiu;LU Changping(Yunfu Hospital of Traditional Chinese Medicine,Yunfu 527300,China)
出处
《临床医学研究与实践》
2024年第13期178-181,共4页
Clinical Research and Practice
基金
2022年度云浮市医药卫生科研立项课题(No.2022B026)。
关键词
信息化手段
药学干预
心内科
活血化瘀中成药
information technology
pharmaceutical intervention
cardiology department
Chinese patent medicine for promoting blood circulation and removing blood stasis